BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 30887841)

  • 1. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.
    Bewersdorf JP; Stahl M; Zeidan AM
    Expert Rev Anticancer Ther; 2019 May; 19(5):393-404. PubMed ID: 30887841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Daver N; Boddu P; Garcia-Manero G; Yadav SS; Sharma P; Allison J; Kantarjian H
    Leukemia; 2018 May; 32(5):1094-1105. PubMed ID: 29487386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
    Bewersdorf JP; Zeidan AM
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101222. PubMed ID: 33279182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications.
    Kim ST; Sheshadri A; Shannon V; Kontoyiannis DP; Kantarjian H; Garcia-Manero G; Ravandi F; Im JS; Boddu P; Bashoura L; Balachandran DD; Evans SE; Faiz S; Ruiz Vazquez W; Divenko M; Mathur R; Tippen SP; Gumbs C; Neelapu SS; Naing A; Wang L; Diab A; Futreal A; Nurieva R; Daver N
    Front Immunol; 2020; 11():590494. PubMed ID: 33552049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immune therapy for myeloid malignancies: present and future.
    Holmström MO; Hasselbalch HC
    Semin Immunopathol; 2019 Jan; 41(1):97-109. PubMed ID: 29987478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy.
    Nakatsuru K; Tsubouchi K; Hirahata M; Nakashima T; Takahata Y; Okamatsu Y; Shiraishi Y; Okamoto I; Harada T
    Thorac Cancer; 2023 Aug; 14(22):2225-2228. PubMed ID: 37337950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 signaling and inhibition in AML and MDS.
    Haroun F; Solola SA; Nassereddine S; Tabbara I
    Ann Hematol; 2017 Sep; 96(9):1441-1448. PubMed ID: 28643044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Abaza Y; Zeidan AM
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Gallazzi M; Ucciero MAM; Faraci DG; Mahmoud AM; Al Essa W; Gaidano G; Mouhssine S; Crisà E
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
    Spillane DR; Assouline S
    Expert Rev Hematol; 2023; 16(11):819-834. PubMed ID: 37819154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.
    Stahl M; Goldberg AD
    Curr Oncol Rep; 2019 Mar; 21(4):37. PubMed ID: 30904967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors in AML-A New Frontier.
    Thummalapalli R; Knaus HA; Gojo I; Zeidner JF
    Curr Cancer Drug Targets; 2020; 20(7):545-557. PubMed ID: 32316893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
    Nahas MR; Stroopinsky D; Rosenblatt J; Cole L; Pyzer AR; Anastasiadou E; Sergeeva A; Ephraim A; Washington A; Orr S; McMasters M; Weinstock M; Jain S; Leaf RK; Ghiasuddin H; Rahimian M; Liegel J; Molldrem JJ; Slack F; Kufe D; Avigan D
    Br J Haematol; 2019 May; 185(4):679-690. PubMed ID: 30828801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.
    Swoboda DM; Sallman DA
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101221. PubMed ID: 33279177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
    Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
    Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.
    Yao S; Jianlin C; Zhuoqing Q; Yuhang L; Jiangwei H; Guoliang H; Hongmei N; Bin Z; Liangding H
    Front Immunol; 2021; 12():639217. PubMed ID: 33868266
    [No Abstract]   [Full Text] [Related]  

  • 20. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
    Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.